Want to join the conversation?
$MRK 2Q15 Call: Last month, the FDA accepted the supplemental BLA for KEYTRUDA, an advanced non-small cell lung cancer, and granted KEYTRUDA Priority Review. This past week, the European Commission approved KEYTRUDA for the treatment of advanced melanoma in adults, both as a first line therapy and in previously treated patients.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.